Researchers at Fred Hutchinson Cancer Research Center in Seattle have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans, based on findings by principal investigator Amanda Paulovich, MD, PhD, an associate member of the Hutchinson Center's clinical research division, and colleagues published in Nature Biotechnology.

Biotech company ImaginAb has locked a research deal with GE Healthcare to develop PET diagnostic imaging agents for cardiovascular disease, the companies said on June 5.

The Alzheimer's Drug Discovery Foundation, based in New York City, will provide Melbourne, Australia-based Prana Biotechnology an investment of $700,000 over two years to conduct a clinical trial investigating the potential of PBT2 to reduce the accumulation of beta-amyloid in the brain of people with Alzheimer's disease. PET amyloid neuroimaging and other biomarkers will be used as the primary outcome measures.